Irene Slavc

List of Publications by Year
in descending order

127 papers	5,988 citations	145106 33 h-index	93651 72 g-index

127 all docs	127 docs citations	127 times ranked	9557 citing authors

#	Article	IF	Citations
1	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 2019, 178, 835-849.e21.	13.5	1,408
2	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
3	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018, 360, 331-335.	6.0	461
4	Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium â€˜Care for CMMRDâ€™ (C4CMMRD). Journal of Medical Genetics, 2014, 51, 355-365.	1.5	351
5	Resolving medulloblastoma cellular architecture by single-cell genomics. Nature, 2019, 572, 74-79.	13.7	273
6	Immunohistochemical Analysis of INI1 Protein in Malignant Pediatric CNS Tumors: Lack of INI1 in Atypical Teratoid/Rhabdoid Tumors and in a Fraction of Primitive Neuroectodermal Tumors without Rhabdoid Phenotype. American Journal of Surgical Pathology, 2006, 30, 1462-1468.	2.1	166
7	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	7.7	157
8	Incidence of atypical teratoid/rhabdoid tumors in children. Cancer, 2010, 116, 5725-5732.	2.0	126
9	Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration. Pediatric Neurology, 2017, 67, 23-35.	1.0	117
10	Atypical teratoid rhabdoid tumor: improved longâ€term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992â€“2012. Cancer Medicine, 2014, 3, 91-100.	1.3	99
11	Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatric Blood and Cancer, 2012, 59, 511-517.	0.8	98
12	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell, 2020, 38, 44-59.e9.	7.7	94
13	Ki-67 Immunolabeling Index Is an Accurate Predictor of Outcome in Patients With Intracranial Ependymoma. American Journal of Surgical Pathology, 2004, 28, 914-920.	2.1	78
14	Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncology, The, 2006, 7, 521-523.	5.1	76
15	Childhood supratentorial ependymomas with YAP1â€MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathology, 2019, 29, 205-216.	2.1	75
16	Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathologica, 2000, 100, 101-105.	3.9	70
17	p53 gene mutations in pediatric brain tumors. Medical and Pediatric Oncology, 1995, 25, 431-436.	1.0	65
18	Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. Journal of Neuro-Oncology, 2003, 64, 239-247.	1.4	60

#	Article	IF	Citations
19	Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. Journal of Neuro-Oncology, 2014, 120, 139-145.	1.4	58
20	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	0.8	58
21	Exon scanning for mutations of thenf2 gene in pediatric ependymomas, rhabdoid tumors and meningiomas. International Journal of Cancer, 1995, 64, 243-247.	2.3	54
22	Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities. Frontiers in Oncology, 2019, 9, 1436.	1.3	50
23	Protein profiles of medulloblastoma cell lines DAOY and D283: Identification of tumor-related proteins and principles. Proteomics, 2003, 3, 1781-1800.	1.3	48
24	Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. Journal of Neuro-Oncology, 1998, 38, 213-218.	1.4	44
25	Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. Acta Neuropathologica Communications, 2016, 4, 88.	2.4	44
26	Best practices for the use of intracerebroventricular drug delivery devices. Molecular Genetics and Metabolism, 2018, 124, 184-188.	0.5	44
27	Primary central nervous system lymphoma: a clinicopathological study of 75 cases. Pathology, 2010, 42, 547-552.	0.3	42
28	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	1.4	42
29	Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. Journal of Medical Genetics, 2019, 56, 53-62.	1.5	40
30	B-cell differentiation pattern of cutaneous lymphomas in infancy and childhood. Cancer, 1988, 61, 303-308.	2.0	37
31	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. Journal of Neuro-Oncology, 2019, 145, 177-184.	1.4	36
32	Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [¹⁸F]FDGâ€PET imaging. Is it of value in asymptomatic patients?. Pediatric Blood and Cancer, 2018, 65, e26733.	0.8	35
33	Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathologica, 2005, 109, 211-216.	3.9	34
34	Pharmacokinetics and Safety of Intrathecal Liposomal Cytarabine in Children Aged <3 Years. Clinical Pharmacokinetics, 2009, 48, 265-271.	1.6	34
35	Management of choroid plexus tumorsâ€"an institutional experience. Acta Neurochirurgica, 2019, 161, 745-754.	0.9	34
36	Papillary glioneuronal tumor. Neuropathology, 2007, 27, 468-473.	0.7	33

#	Article	IF	Citations
37	Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatric Blood and Cancer, 2010, 54, 681-686.	0.8	33
38	Trends in incidence, survival and mortality of childhood and adolescent cancer in Austria, 1994â¿¿2011. Cancer Epidemiology, 2016, 42, 72-81.	0.8	33
39	Survivin Expression in Intracranial Ependymomas and Its Correlation With Tumor Cell Proliferation and Patient Outcome. American Journal of Clinical Pathology, 2005, 124, 543-549.	0.4	32
40	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-Oncology, 2017, 19, 1183-1194.	0.6	31
41	Acute megakaryocytic leukemia in children clinical, immunologic, and cytogenetic findings in two patients. Cancer, 1991, 68, 2266-2272.	2.0	28
42	Pharmacokinetics and Toxicity of Intrathecal Liposomal Cytarabine in Children and Adolescents Following Age-Adapted Dosing. Clinical Pharmacokinetics, 2014, 53, 165-173.	1.6	28
43	Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathologica Communications, 2020, 8, 78.	2.4	28
44	Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with loss of morphological but retained genetic key features during progression. Acta Neuropathologica, 2011, 122, 787-790.	3.9	27
45	High impact of miRNA-4521 on FOXM1 expression in medulloblastoma. Cell Death and Disease, 2019, 10, 696.	2.7	27
46	TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma. Acta Neuropathologica Communications, 2019, 7, 128.	2.4	26
47	Proteomic characterization of the human cortical neuronal cell line HCN-2. Journal of Chemical Neuroanatomy, 2003, 26, 171-178.	1.0	25
48	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro-Oncology, 2020, 22, 944-954.	0.6	25
49	From Symptom to Diagnosisâ€"The Prediagnostic Symptomatic Interval of Pediatric Central Nervous System Tumors in Austria. Pediatric Neurology, 2017, 76, 27-36.	1.0	24
50	Constitutional mismatch repair deficiencyâ€“associated brain tumors: report from the European C4CMMRD consortium. Neuro-Oncology Advances, 2019, 1, vdz033.	0.4	23
51	Future paradigms for precision oncology. Oncotarget, 2016, 7, 46813-46831.	0.8	23
52	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	0.6	22
53	Cerebellar pilocytic astrocytoma in childhood: Investigating the long-term impact of surgery on cognitive performance and functional outcome. Developmental Neurorehabilitation, 2018, 21, 1-8.	0.5	20
54	Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. Journal of Personalized Medicine, 2020, 10, 290.	1.1	18

#	Article	IF	Citations
55	Proliferative activity as measured by MIB-1 labeling index and long-term outcome of cerebellar juvenile pilocytic astrocytomas. Journal of Neuro-Oncology, 2002, 58, 141-146.	1.4	17
56	Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis. Journal of Personalized Medicine, 2021, 11, 292.	1.1	15
57	Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Acta Neuropathologica, 2021, 142, 339-360.	3.9	14
58	Proliferative activity as measured by MIB-1 labeling index and long-term outcome of visual pathway astrocytomas in children. Journal of Neuro-Oncology, 1999, 42, 143-150.	1.4	13
59	Do we still need IQ-scores? Misleading interpretations of neurocognitive outcome in pediatric patients with medulloblastoma: a retrospective study. Journal of Neuro-Oncology, 2017, 135, 361-369.	1.4	13
60	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. Acta Neuropathologica, 2020, 139, 583-596.	3.9	13
61	Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas. Acta Neurochirurgica, 2021, 163, 2025-2035.	0.9	13
62	Mass spectrometric identification of serine hydrolase OVCA2 in the medulloblastoma cell line DAOY. Cancer Letters, 2006, 241, 235-249.	3.2	11
63	Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples. Neuropathology, 2006, 26, 393-399.	0.7	11
64	Tumor stabilization under treatment with imatinib in progressive hypothalamicâ€chiasmatic glioma. Pediatric Blood and Cancer, 2009, 52, 476-480.	0.8	11
65	Potential Importance of Early Focal Radiotherapy Following Gross Total Resection for Long-Term Survival in Children With Embryonal Tumors With Multilayered Rosettes. Frontiers in Oncology, 2020, 10, 584681.	1.3	11
66	Mutation analysis and loss of heterozygosity of PEDF in central nervous system primitive neuroectodermal tumors. , 1997, 72, 277-282.		10
67	Neuronal correlates of cognitive function in patients with childhood cerebellar tumor lesions. PLoS ONE, 2017, 12, e0180200.	1.1	10
68	Synthesis, Chaperoning, and Metabolism of Proteins Are Regulated by NT-3/TrkC Signaling in the Medulloblastoma Cell Line DAOY. Journal of Proteome Research, 2008, 7, 1932-1944.	1.8	9
69	Neurotrophin 3/TrkCâ€regulated proteins in the human medulloblastoma cell line DAOY. Electrophoresis, 2009, 30, 540-549.	1.3	9
70	High plasma-GFAP levels in metastatic myxopapillary ependymoma. Journal of Neuro-Oncology, 2013, 113, 359-363.	1.4	8
71	Applying the International Classification of Functioningâ€“Children and Youth Version to Pediatric Neuro-oncology. Journal of Child Neurology, 2017, 32, 23-28.	0.7	8
72	Advantages of an ICF-Based Approach in School Reintegration of Pediatric Brain Tumor Patients: The School Participation Scales (S-PS-24/7). Journal of Cancer Therapy, 2013, 04, 825-834.	0.1	8

#	Article	IF	Citations
73	Identification of c-myc-dependent proteins in the medulloblastoma cell line D425Med. Amino Acids, 2012, 42, 2149-2163.	1.2	7
74	Does the interval from tumour surgery to radiotherapy influence survival in paediatric high grade glioma?. Strahlentherapie Und Onkologie, 2018, 194, 552-559.	1.0	7
75	Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3ÂYears with CNS Malignancies. Drugs in R and D, 2017, 17, 469-474.	1.1	6
76	MBCL-43. RECURRENT MEDULLOBLASTOMA â€“ LONG-TERM SURVIVAL WITH A â€œMEMMATâ€•BASED ANTIANGIOGENIC APPROACH. Neuro-Oncology, 2020, 22, iii397-iii397.	0.6	5
77	The medulloblastoma cell line DAOY but not eleven other tumor cell lines expresses minichromosome maintenance protein 4. Cancer Letters, 2006, 238, 76-84.	3.2	4
78	Mitosis-Dependent Protein Expression in Neuroblastoma Cell Line N1E-115. Journal of Proteome Research, 2008, 7, 3412-3422.	1.8	4
79	MBCL-27. RESPONSE OF RECURRENT MALIGNANT CHILDHOOD CNS TUMORS TO A MEMMAT BASED METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY VARIES DEPENDENT ON TUMOR TYPE: EXPERIENCE IN 71 PATIENTS. Neuro-Oncology, 2018, 20, i122-i122.	0.6	4
80	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. Neuro-Oncology, 2018, 20, i72-i72.	0.6	4
81	Validation of Hypothetical Nucleic Acid Binding Proteins in Human Bronchial Epithelial, Mesothelial, Amnion, Kidney and Lymphocyte Cell Lines by Proteomics. Current Proteomics, 2004, 1, 297-313.	0.1	3
82	MB-70MEMMAT - A PHASE II STUDY OF METRONOMIC AND TARGETED ANTI-ANGIOGENESIS THERAPY FOR CHILDREN WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA. Neuro-Oncology, 2016, 18, iii113.1-iii113.	0.6	3
83	Editorial: Precision/Personalized Pediatric Oncology and Immune Therapies: Rather Customize Than Randomize. Frontiers in Oncology, 2020, 10, 377.	1.3	3
84	Unique Finding of a Primary Central Nervous System Neuroendocrine Carcinoma in a 5-Year-Old Child: A Case Report. Frontiers in Neuroscience, 2022, 16, 810645.	1.4	3
85	Highlights of Children with Cancer UKâ€™s Workshop on Drug Delivery in Paediatric Brain Tumours. Ecancermedicalscience, 2016, 10, 630.	0.6	2
86	EAPH-11. INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE, AQUEOUS CYTARABINE AND TOPOTECAN IS FEASIBLE AND SAFE: EXPERIENCE IN 26 PEDIATRIC PATIENTS WITH MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2018, 20, i67-i67.	0.6	2
87	Predisposition of Wingless Subgroup Medulloblastoma for Primary Tumor Hemorrhage. Neurosurgery, 2020, 86, 478-484.	0.6	2
88	The assessment of executive functioning in pediatric patients with posterior fossa tumors: A recommendation to combine caregiver-based ratings and performance-based tests. Developmental Neurorehabilitation, 2022, 25, 19-28.	0.5	2
89	Evaluating the diagnostic validity of the cerebellar cognitive affective syndrome (CCAS) in pediatric posterior fossa tumor patients. Neuro-Oncology Advances, 2022, 4, .	0.4	2
90	BMET-08. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE IS FEASIBLE AND SAFE: EXPERIENCE IN 57 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2016, 18, vi27-vi28.	0.6	1

#	Article	IF	Citations
91	Protein Profiling of the Supratentorial Primitive Neuroectodermal Tumor (PNET) Cell Line PFSK-1. Cancer Genomics and Proteomics, 2004, 1, 125-136.	1.0	1
92	Impact of childhood cerebellar tumor surgery on cognition revealed by precuneus hyperconnectivity. Neuro-Oncology Advances, 2022, 4, vdac050.	0.4	1
93	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy â€“ Results of the MET-HIT2000-BIS4 trial. Neuro-Oncology, 2022, 24, i104-i104.	0.6	1
94	Sociocultural variables have a major impact on participation in patients treated for paediatric posterior fossa tumours. Child: Care, Health and Development, 0, , .	0.8	1
95	Deletion mapping and candidate gene analysis of chromosome 17 in primitive neuroectodermal tumors of the CNS. Cancer Genetics and Cytogenetics, 1995, 84, 133.	1.0	0
96	Genomic Alterations in Atypical Teratoid/Rhabdoid Tumors: The Medical University of Vienna Experience. Cancer Genetics, 2014, 207, 456.	0.2	0
97	ANGI-14UPDATE ON A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY FOR RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR. Neuro-Oncology, 2015, 17, v44.1-v44.	0.6	0
98	MBCL-28. PREDISPOSITION OF WNT-ACTIVATED MEDULLOBLASTOMA FOR PRIMARY INTRATUMORAL HEMORRHAGE. Neuro-Oncology, 2018, 20, i122-i122.	0.6	0
99	MBCL-40. UNFAVORABLE CLINICAL COURSE OF A WNT-ACTIVATED MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i125-i126.	0.6	0
100	NSRG-19. CSF DISTURBANCES AFTER TRANSCALLOSAL RESECTION: ARE THERE PREDICTING FACTORS?. Neuro-Oncology, 2018, 20, i149-i149.	0.6	0
101	NSRG-20. LONG-TERM SUPRATENTORIAL WHITE MATTER CHANGES AND COGNITIVE FUNCTION FOLLOWING CEREBELLAR TUMOUR RESECTIONS IN CHILDHOOD. Neuro-Oncology, 2018, 20, i149-i149.	0.6	0
102	INNV-36. A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY MAY PROLONG SURVIVAL FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR. Neuro-Oncology, 2018, 20, vi145-vi145.	0.6	0
103	EPID-09. CMMRD (CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY) ASSOCIATED-BRAIN TUMORS: REPORT FROM THE EUROPEAN C4CMMRD CONSORTIUM. Neuro-Oncology, 2018, 20, i82-i82.	0.6	0
104	MBRS-28. SINGLE-CELL TRANSCRIPTOME ANALYSIS OF MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i134-i134.	0.6	0
105	QOL-43. CEREBELLAR MUTISM, NEUROCOGNITIVE AND ACADEMIC OUTCOME IN A CONSECUTIVE SAMPLE OF PEDIATRIC CEREBELLAR TUMOR PATIENTS. Neuro-Oncology, 2018, 20, i166-i166.	0.6	0
106	RARE-12. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR). Neuro-Oncology, 2019, 21, vi223-vi224.	0.6	0
107	PDTM-32. RESOLVING MEDULLOBLASTOMA CELLULAR ARCHITECTURE BY SINGLE-CELL GENOMICS. Neuro-Oncology, 2019, 21, vi194-vi194.	0.6	0
108	GENE-45. DISSECTING THE DRIVERS OF ADULT H3K27M-GLIOMAS AT THE SINGLE-CELL LEVEL. Neuro-Oncology, 2019, 21, vi107-vi107.	0.6	0

#	Article	IF	Citations
109	RARE-20. A RARE CASE OF A PRIMARY CENTRAL NERVOUS SYSTEM NEUROENDOCRINE CARCINOMA AND SUCCESSFULL THERAPY IN A FIVE-YEAR-OLD CHILD. Neuro-Oncology, 2021, 23, i45-i45.	0.6	0
110	HGG-06. EARLY GABAERGIC NEURONAL LINEAGE DEFINES DEPENDENCIES IN HISTONE H3 G34R/V GLIOMA. Neuro-Oncology, 2021, 23, i18-i18.	0.6	0
111	ETMR-17. SINGLE-CELL TRANSCRIPTOME ANALYSIS OF ETMR PATIENT SAMPLES. Neuro-Oncology, 2020, 22, iii326-iii326.	0.6	0
112	MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT. Neuro-Oncology, 2020, 22, iii388-iii389.	0.6	0
113	DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2020, 22, iii284-iii284.	0.6	0
114	ETMR-10. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR). Neuro-Oncology, 2020, 22, iii324-iii325.	0.6	0
115	EPEN-21. IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION IN PEDIATRIC EPENDYMOMA REVEALED BY SINGLE-CELL RNA-SEQ. Neuro-Oncology, 2020, 22, iii311-iii312.	0.6	0
116	HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii351-iii352.	0.6	0
117	ETMR-08. INTERNATIONAL CONSENSUS PROTOCOL FOR EMBRYONAL TUMOR WITH MULTILAYER ROSETTES. Neuro-Oncology, 2020, 22, iii324-iii324.	0.6	0
118	EPCO-35. SINGLE-CELL RNA-SEQ OF PEDIATRIC EPENDYMOMA REVEALS PROGNOSTIC IMPACT OF IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION. Neuro-Oncology, 2020, 22, ii76-ii77.	0.6	0
119	Proteomic Determination of Metabolic Protein Expression in Ten Different Tumor Cell Lines. Cancer Genomics and Proteomics, 2004, 1, 311-338.	1.0	0
120	Proteomic Profiling of Signaling Proteins in Ten Different Tumor Cell Lines. Cancer Genomics and Proteomics, 2004, 1, 427-454.	1.0	0
121	QOL-27. Sociocultural variables have a major impact on participation in patients treated for pediatric posterior fossa tumors. Neuro-Oncology, 2022, 24, i139-i139.	0.6	0
122	PATH-09. Liquid biopsy of cerebrospinal fluid enables detecting and monitoring ofMYC/MYCN amplification in pediatric CNS malignancies. Neuro-Oncology, 2022, 24, i160-i160.	0.6	0
123	IMG-03. Impact of childhood cerebellar tumor surgery on cognition: Can fMRI serve as a surrogate marker?. Neuro-Oncology, 2022, 24, i77-i77.	0.6	0
124	DDEL-05. Intraventricular therapy with topotecan is feasible and safe: Experience in 50 pediatric patients with various malignant brain tumors. Neuro-Oncology, 2022, 24, i34-i35.	0.6	0
125	SURG-02. The site of origin of medulloblastoma: Does the neurosurgical perspective support the current concept from molecular data?. Neuro-Oncology, 2022, 24, i142-i142.	0.6	0
126	QOL-30. Positive Effects of a psychological preparation program for MRI in children with cognitive issues â€“ how to best meet the patientsâ€™ needs. Neuro-Oncology, 2022, 24, i140-i140.	0.6	0

#	Article	IF	Citations
127	QOL-24. Evaluating the diagnostic validity & predictive value of the Cerebellar Cognitive Affective Syndrome (CCAS) in pediatric posterior fossa tumour patients. Neuro-Oncology, 2022, 24, i138-i139.	0.6	0